Burgdorf – A new chapter in the treatment of obesity begins with the approval of the world's first dual GCG/GLP-1 receptor agonist drug delivered using an Ypsomed autoinjector in China. Innovent Biologics, Inc. (XHKG: 1801), a leading Chinese biopharmaceutical company, has received approval from the Chinese National Medical Products Administration (NMPA) for Mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of people with obesity, which is now launching in an YpsoMate 1.0 autoinjector variant.
High growth potential in China
China represents the world’s second-largest population affected by overweight and obesity – and the numbers continue to rise. The increasing demand for GLP-1-based therapies was a key factor behind the construction of Ypsomed’s new manufacturing site in Changzhou, which was officially inaugurated on 26 June 2025. Once approved by Chinese authorities, the site will supply volumes of autoinjectors for this therapy. Until then, the devices will be delivered from Ypsomed’s production facilities in Switzerland and Germany.
China for China: Proximity to customers
With the new Changzhou facility, Ypsomed is pursuing its “China for China” strategy – aiming to manufacture directly in the country for the local market. This approach strengthens supply chain resilience, ensures faster delivery times, and reinforces proximity to customers in China. It also underlines Ypsomed’s commitment to long-term partnerships, local value creation in the region and sustainability.
Trusted collaboration with Innovent Biologics
Innovent Biologics, Inc. chose Ypsomed as its device partner based on Ypsomed’s reliable autoinjector platforms and expertise in scaling up production for therapies. The collaboration between the two companies has been in place since 2019.
Making selfcare simpler and easier
Selfcare enables people living with chronic conditions to manage their health more independently while easing pressure on healthcare services. Thanks to user-friendly devices like YpsoMate, patients can carry out injections at home with confidence and minimal training.
